Government-Owned Inventions; Availability for Licensing, 19073 [2017-08351]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
the authority for ICCVAM involvement
in activities relevant to the development
of alternative test methods. ICCVAM
acts to ensure that new and revised test
methods are validated to meet the needs
of federal agencies, increase the
efficiency and effectiveness of federal
agency test method review, and
optimize utilization of scientific
expertise outside the federal
Government. Additional information
about ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative testing
approaches for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: April 13, 2017.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2017–08354 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
asabaliauskas on DSK3SPTVN1PROD with NOTICES
National Cancer Institute; Cancellation
of Meeting
Notice is hereby given of the
cancellation of the National Cancer
Institute Special Emphasis Panel, May
1, 2017, 8:00 a.m. to May 2, 2017, 1:00
p.m., Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814 which
was published in the Federal Register
on March 22, 2017, 82 FR 54.
This meeting is being amended to
cancel the meeting on May 1–2, 2017.
Dated: April 20, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Chris Kornak, 240–627–3705,
chris.kornak@nih.gov. Licensing
information and copies of the U.S.
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
A Second CD4-Binding Region of
HIV–1 gp120 Critical for Viral
Infectivity: New Methods for Treatment
and Vaccine Development
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–08348 Filed 4–24–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Description of Technology: It is
believed that immunization with an
effective immunogen based on the HIV–
1 envelope glycoprotein can elicit a
neutralizing antibody response, which
may be protective against HIV–1
infection. NIAID researchers have
discovered a new critical component of
the CD4-binding site in gp120, named
CD4–BS2, which is exclusively formed
in the trimeric envelope conformation.
It was further found that this newly
recognized region is critical for the
progression of the fusogenic mechanism
that leads to HIV–1 entry and infection
of the cells. This discovery may lead to
new methods of treatment, for treating
HIV–1, as well as to the production of
new vaccine immunogens.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
19073
development and evaluation under a
research collaboration.
Potential Commercial Applications:
New target for HIV therapeutic and
vaccine development.
Competitive Advantages: A new
molecular target discovered in this
invention may facilitate the
development of next-generation HIV
therapeutics and vaccines.
Development Stage: Proof-of-concept
studies demonstrate that CD4 binding to
CD4–BD2 is critical for triggering gp120
conformational changes that enable
coreceptor binding and HIV–1
infectivity. Animal studies are ongoing.
Inventors: Paolo Lusso, NIAID, NIH;
and Qingbo Liu, NIAID, NIH.
Publications: Liu, Qingbo, et al.
‘‘Quaternary contact in the initial
interaction of CD4 with the HIV–1
envelope trimer.’’ Nature Structural &
Molecular Biology (2017).
Intellectual Property: HHS Reference
No. E–230–2015/0—U.S. Patent
Application No. 62/292,750 filed 02/08/
2016; PCT Application No. PCT/
US2017/017038 filed 02/08/2017.
Licensing Contact: Chris Kornak, 240–
627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office (TTIPO) is
seeking parties interested in
collaborative research to further codevelop HIV–1 vaccines and/or
inhibitors that target the newly
recognized region. For collaboration
opportunities, please contact Chris
Kornak, 240–627–3705, chris.kornak@
nih.gov.
Dated: April 10, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–08351 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\25APN1.SGM
25APN1
]]>Agencies
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Page 19073]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08351]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705,
chris.kornak@nih.gov. Licensing information and copies of the U.S.
patent applications listed below may be obtained by communicating with
the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
A Second CD4-Binding Region of HIV-1 gp120 Critical for Viral
Infectivity: New Methods for Treatment and Vaccine Development
Description of Technology: It is believed that immunization with an
effective immunogen based on the HIV-1 envelope glycoprotein can elicit
a neutralizing antibody response, which may be protective against HIV-1
infection. NIAID researchers have discovered a new critical component
of the CD4-binding site in gp120, named CD4-BS2, which is exclusively
formed in the trimeric envelope conformation. It was further found that
this newly recognized region is critical for the progression of the
fusogenic mechanism that leads to HIV-1 entry and infection of the
cells. This discovery may lead to new methods of treatment, for
treating HIV-1, as well as to the production of new vaccine immunogens.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications: New target for HIV therapeutic
and vaccine development.
Competitive Advantages: A new molecular target discovered in this
invention may facilitate the development of next-generation HIV
therapeutics and vaccines.
Development Stage: Proof-of-concept studies demonstrate that CD4
binding to CD4-BD2 is critical for triggering gp120 conformational
changes that enable coreceptor binding and HIV-1 infectivity. Animal
studies are ongoing.
Inventors: Paolo Lusso, NIAID, NIH; and Qingbo Liu, NIAID, NIH.
Publications: Liu, Qingbo, et al. ``Quaternary contact in the
initial interaction of CD4 with the HIV-1 envelope trimer.'' Nature
Structural & Molecular Biology (2017).
Intellectual Property: HHS Reference No. E-230-2015/0--U.S. Patent
Application No. 62/292,750 filed 02/08/2016; PCT Application No. PCT/
US2017/017038 filed 02/08/2017.
Licensing Contact: Chris Kornak, 240-627-3705,
chris.kornak@nih.gov.
Collaborative Research Opportunity: The Technology Transfer and
Intellectual Property Office (TTIPO) is seeking parties interested in
collaborative research to further co-develop HIV-1 vaccines and/or
inhibitors that target the newly recognized region. For collaboration
opportunities, please contact Chris Kornak, 240-627-3705,
chris.kornak@nih.gov.
Dated: April 10, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-08351 Filed 4-24-17; 8:45 am]
BILLING CODE 4140-01-P
